Glenmark Pharmaceuticals Ltd vs Mangalam Drugs And Organics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2340 as of 18 May 15:30 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 41.5 on March 2025 to 44.2 on March 2023 . This represents a CAGR of 1.59% over 4 yearsThe P/E Ratio of Mangalam Drugs and Organics Ltd changed from 17.5 on March 2025 to 0 on March 2023 . This represents a CAGR of -100.00% over 4 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 27019 crore on March 2024 to ₹ 13120 crore on March 2023 . This represents a CAGR of -13.45% over 5 yearsThe Market Cap of Mangalam Drugs and Organics Ltd changed from ₹ 146.65 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 years The revenue of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 3945 crore. This represent the decline of -100% The revenue of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ 67.38 crore as compare to the Dec '25 revenue of ₹ 58.6 crore. This represent the growth of 14.98% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 729.88 crore. This represent the decline of -100% The ebitda of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ -5.53 crore as compare to the Dec '25 ebitda of ₹ -1.32 crore. This represent the growth of 318.94% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Mangalam Drugs and Organics Ltd changed from ₹ 2.68 crore to ₹ -13.42 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Mangalam Drugs and Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Limited was initially incorporated as 'Advent Pharma Private Limited' on April 18, 1972.
On July 1, 1997, the Company changed the name from Advent Pharma Private Limited to Mangalam Drugs and Organics Private Limited.
Thereafter, it converted the status into a Public Limited Company, changing the name to Mangalam Drugs and Organics Limited on August 10, 2001.
The company was established to set up a plant for manufacture of organic and inorganic chemicals. The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates.
The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Mangalam Drugs and Organics Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Mangalam Drugs and Organics Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 66,047 Cr while Market cap of Mangalam Drugs and Organics Ltd is 48 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Mangalam Drugs and Organics Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Mangalam Drugs and Organics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Mangalam Drugs and Organics Ltd?

As of May 18, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2340.45. On the other hand, Mangalam Drugs and Organics Ltd stock price is INR ₹30.38.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Mangalam Drugs and Organics Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Mangalam Drugs and Organics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.